The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist.
The binding of epidermal growth factor (EGF) to human myometrium and leiomyomata was assessed in a group of women rendered hypo-oestrogenic with the LHRH agonist Zoladex (ICI 118630). The results were compared with those obtained with tissues from women with normal cycles. In normal women, the specific binding of radiolabelled [125I] EGF to both myometrial and fibroid homogenates did not vary during the menstrual cycle, but the specific binding of [125I] EGF to fibroid in women treated with LHRH agonist was significantly less than in the untreated group. Since the hypo-oestrogenic state induced by the agonist is associated with a decrease in fibroid size, the results suggest that the effect of oestrogen on fibroid tissue may partly be mediated by EGF.
Lumsden
M A
MA
Department of Obstetrics and Gynaecology, University of Edinburgh.
West
C P
CP
Bramley
T
T
Rumgay
L
L
Baird
D T
DT
D000328:Adult; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000378:metabolism*; D004958:Estradiol / Q000097:blood; D005260:Female; D017273:Goserelin; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy / Q000378:metabolism*; D008597:Menstrual Cycle; D009215:Myometrium / Q000378:metabolism; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000378:metabolism*
D017273:Goserelin; D004958:Estradiol; D004815:Epidermal Growth Factor; D002064:Buserelin